Torella, Laura https://orcid.org/0009-0002-5881-1204
Klermund, Julia
Bilbao-Arribas, Martin https://orcid.org/0000-0002-3332-5667
Tamayo, Ibon
Andrieux, Geoffroy
Chmielewski, Kay O
Vales, Africa https://orcid.org/0009-0000-4507-8117
Olagüe, Cristina https://orcid.org/0009-0002-9627-6126
Moreno-Luqui, Daniel
Raimondi, Ivan
Abad, Amaya https://orcid.org/0000-0002-6865-9149
Torrens-Baile, Julen
Salido, Eduardo
Huarte, Maite https://orcid.org/0000-0003-3753-6493
Hernaez, Mikel
Boerries, Melanie https://orcid.org/0000-0002-3670-0602
Cathomen, Toni https://orcid.org/0000-0002-7757-4630
Zabaleta, Nerea https://orcid.org/0000-0001-8093-4695
Gonzalez-Aseguinolaza, Gloria https://orcid.org/0000-0002-1600-4562
Funding for this research was provided by:
MEC | Spanish National Plan for Scientific and Technical Research and Innovation (RTI2018-101936-B-I00)
MEC | Instituto de Salud Carlos III (TERAV Network RD21/0017/0001)
oxalosis and hiperoxaluria foundation
German Research Foundation (CA311/4-1 and CRC1160,Project ID 256073931- A07)
German Research Foundation (CRC/TRR167 (ID 259373024-Z01),CRC1453 (ID 431984000-S1),and CRC1479 (ID: 441891347- S1))
Bundesministerium für Bildung und Forschung (MIRACUM-FKZ 01ZZ1801B)
Bundesministerium für Bildung und Forschung (EkoEstMed-FKZ 01ZZ2015)
European Commission (AAVolution EC project number 101071041)
European Commission (GenE-HumDi CA21113)
Article History
Received: 28 June 2023
Revised: 14 November 2023
Accepted: 15 November 2023
First Online: 5 January 2024
Disclosure and competing interests statement
: ES holds shares of Orfan Biotech. TC is a consultant to Cimeio Therapeutics and Excision BioTherapeutics, and holds a patent on CAST-Seq. GG-A is a founder and shareholder of Vivet Therapeutics. All other authors declare they have no competing interests.